Organic Active Ingredients TRIZ Cases

Topical methylene blue and rapamycin clear progerin aggregates via autophagy, restoring nuclear envelope integrity in premature aging cells.

Formula I compounds block IDH mutant alpha hydroxyl neoactivity, reducing 2HG accumulation in cancer cells.

Novel phosphonate compounds inhibit resistant influenza neuraminidases.

Glucocorticoid receptor antagonists increase pituitary ACTH secretion, resolving invasive catheterization and CRH shortages in Cushing's syndrome diagnosis.

An LM-1 antibody binds the NONO/nmt55 antigen on cancer cells to induce apoptosis and reduce cellular proliferation.

Novel coelenterazine derivatives with specific bicyclic structures exhibit high luminescence brightness and enzyme specificity.

Anti-OX40L antibodies reduce cytokine secretion and leukocyte proliferation by blocking the OX40/OX40L interaction, addressing inadequate GvHD management.

Granular estetrol formulation with sugar alcohols dissolves rapidly in saliva for direct mucosal absorption.

A pharmaceutical composition containing diindolylmethane and gingerol derivatives enhances insulin release through targeted molecular modulation.

Modified AAV capsid proteins enhance heparan sulfate binding to improve retinal cell transduction efficiency.

Sequential additive addition to hypromellose dispersion prevents plating deterioration while improving bioavailability.

Polyrotaxane carriers resolve rapid clearance and toxicity trade-offs by sustaining cholesterol removal in Niemann-Pick type C disease.

Heating the active ingredient above its melting point and solidifying it within polyvinyl alcohol eliminates binder instability.

Novel lurasidone dihydrochloride hydrate salt overcomes poor bioavailability of the monohydrochloride form by enhancing water solubility and stability.

Selective 5-HT2A antagonism by substituted heterocycle fused gamma-carboline reduces side effects from high dopamine D2 pathway occupancy.

Edonentan crystalline form 4 reduces intraocular pressure and improves retinal perfusion while addressing inadequate treatment effectiveness.

Segmented peptide epitopes target tumor-associated antigens with high affinity, reducing off-target side effects in immunotherapy.

Single-stranded DNA aptamers bind activated NF-kB/RelA to quantify protein levels, resolving low sensitivity in conventional detection methods.

Clay-anesthetic composites protect ester bonds from hydrolysis while creating an occlusive effect that extends pain control duration.

SK1 inhibitors and S1P receptor agonists target sphingosine pathways to induce cancer cell apoptosis while sparing normal tissue.

A meloxicam piperazine derivative dissolves in mixed solvents to enable intravenous injection.

Formula I compounds inhibit VMAT2 to treat neurological disorders while minimizing sedation and Parkinsonism side effects.

A quinazoline derivative overcomes drug resistance by irreversibly inhibiting EGFR tyrosine kinase through covalent bonding at the ATP binding site.

A granulated pharmaceutical substance containing an alkaline agent and surfactant enhances drug solubility through localized chemical environment control.

Replacing subjective behavioral assessments with molecular genetic testing resolves the diagnostic accuracy versus method complexity contradiction.

Streptavidin-desthiobiotin interactions enable sustained drug release over months, reducing injection frequency and ocular complications.

Novel amine prodrugs attach specific appendage moieties to riluzole molecules, creating hybrid structures with enhanced physiochemical properties.

Synthetic human milk oligosaccharides increase Bifidobacterium adolescentis abundance in the gastrointestinal tract.

Segmented pyrimidine structures target specific JNK isoforms, resolving limited treatment effectiveness in liver fibrosis.

Heterocyclic compounds inhibit monoacylglycerol lipase to raise 2-AG levels and reduce AA-derived eicosanoids for treating neuroinflammation.

Administering an agent that blocks IL-11 receptor binding removes pro-fibrotic signaling to alleviate fibrosis.

A pyrimidylpyrazole compound inhibits melanin production in cosmetic preparations.

Pyridine-2-carboxamide derivatives activate glucokinase to regulate blood sugar levels and improve glucose metabolism in type 2 diabetes treatment.

Injectable naltrexone sustained release formulation using biocompatible solvents and 3-acyl derivatives to maintain effective plasma concentrations.

Crystalline acalabrutinib maleate monohydrate maintains high dissolution rates and stability across varying stomach pH conditions.

Adiporon activates adiponectin receptors to improve bone density while reducing inflammation and oxidative stress in diabetic osteoporosis.

Cyclic polypeptides inhibit PCSK9 binding to LDLR, preventing receptor degradation and reducing hypercholesterolemia risk.

Stabilizers like L-methionine shield sarcophagine-copper complexes from radiolysis, maintaining radiochemical purity and bioavailability.

Isolated 3-(3,4-dihydroxy phenyl) propanoic acid derivatives selectively target Src kinase to treat chronic myeloid leukemia and breast cancer.

Targeting CLDN6 on cancer stem cells eliminates chemoresistant populations, preventing tumor recurrence and metastasis.

Liquid-to-gel phase transition extends drug retention time and bioavailability while avoiding blurred vision associated with traditional ointments.

Amide compounds restore mutant CFTR protein folding to improve chloride transport, addressing ΔF508 mutation defects.

Aptamer pairs with anti-aptamers enable sensitive detection of small molecules lacking multiple epitopes.

Pyrroloy[1,2-a]imidazoledione compounds protect nerve cells from chemotherapy damage.

S1PC activates autophagy to clear tau proteins while minimizing side effects in neurodegenerative disease treatment.

Allosteric modulation of the mGluR2 receptor improves brain penetration and reduces tolerance compared to orthosteric agonists.

Dual-action agents target production and excretion pathways to resolve monofunctional therapy limitations in gout management.

A silicone polymer compound enables controlled drug release via ring-opening polymerization of cyclic silane monomers.

Gambogic acid induces apoptosis in HPV-positive cancer cells, reducing toxicity from standard cisplatin chemotherapy.

MCTR3 activates epigenetic programs in monocytes to resolve inflammation while repairing bone and cartilage damage.

Substituted pyrido[3,4-d]pyrimidin-4-one derivatives inhibit histone demethylase enzymes to treat prostate and breast cancer.

Segmenting the formulation into granulated and non-granulated portions prevents segregation while improving in vitro dissolution.

Compound 1 treats inflammatory bowel disease without lengthy titration, reducing cardiovascular adverse events.

A multifunctional compound blocks glutamate receptors and calcium channels to protect neuron cells from toxicity.

Polyphenolic extracts from vinification residues form a homogeneous coating on titanium dental implants.

Antisense oligonucleotides targeting NEK6 mRNA inhibit SMAD2/3 phosphorylation, addressing insufficient efficacy of existing pirfenidone therapies.

Trisodium citrate co-granulation with branched-chain amino acids overcomes gastrointestinal instability to increase serum concentrations.

A lurasidone depot formulation uses particle segmentation to maintain stable suspension and high syringeability for injection.

Replacing mechanical injection with a nasal spray eliminates needle-stick risks while providing rapid opioid reversal through the nasal mucosa.

A carbamoyloxy arylalkanoyl arylpiperazine compound inhibits 15-lipoxygenase activity to treat diabetic complications.

Acetate, p-Tosylate, and malate salts of a pyrido-pyrazinamine compound form stable crystalline structures.

Electrospray atomizes modified cellulose solution to form a hemostatic film, resolving degradation during dissolution.

Pyrimidopyran compounds target KRASG12D mutations lacking effective small molecule treatments, disrupting oncogenic signaling pathways.

Replacing hot-melt extrusion with wet granulation and drying minimizes solvent trapping and simplifies scale-up.

Hypotonic enema formulations maintain osmolality between 123 and 167 mOsm/kg to enhance drug penetration while preserving epithelial integrity.

Macrocyclic prodrug compounds modify radicicol structures to enhance solubility and bioavailability while maintaining HSP90 inhibition efficacy.

A pharmaceutical formulation combining human insulin, nicotinamide, and arginine to achieve rapid absorption kinetics.

Flowable mucoadhesive polymers retain bromfenac in the eye, resolving inadequate absorption and retention issues.

Fluorine substitution at the 6- and 8-positions stabilizes (5Z)-7-oxozeaenol in plasma while maintaining potent inhibitory activity against MAP3K and TAK-1.

Nanoparticulate RNA vaccines deliver CAR antigens to lymphoid compartments, stimulating adoptively transferred CAR T cells.

Surface-modified mesoporous silica particles conjugate viral vectors, enabling localized and efficient genetic transduction of T cells.

A phentermine tablet uses a wax and fatty acid matrix to deliver stable drug release.

STAT4 inhibitors reduce neuroinflammation to delay Alzheimer's disease progression and alleviate symptoms through targeted CNS intervention.

Benzimidazolone compounds inhibit T-type calcium channels while minimizing dopamine D2 receptor binding, reducing extrapyramidal side effects.

Bifunctional atorvastatin PROTACs link to E3 ligases to degrade HMG-CoA reductase.

Bolaamphiphile vesicles encapsulate HIV drugs to overcome blood-brain barrier limits and improve CNS bioavailability.

Cross-linked hyaluronic acid beads provide durable dermal filler effects through segmented cross-linking structures.

An airtight case with a desiccant packet suppresses NTTP production in sitagliptin preparations by maintaining equilibrium relative humidity below 0.3%.

Polysubstituted imidazo[1,2-a]pyridine derivatives target Nurr nuclear receptors to address the lack of effective therapeutic compounds for related diseases.

A topical composition using chloride salts and persulfate oxidizing agents to generate reactive chlorine species upon application.

Optimized oral formulation of FGFR4 inhibitor maintains therapeutic plasma levels while minimizing adverse effects in cancer treatment.

Binder-prodrug conjugates utilize legumain-cleavable peptide linkers to deliver inactive kinesin spindle protein inhibitors.

Rec2 AAV vector uses tissue-specific promoters to deliver transgenes.

Tangential flow filtration isolates high molecular weight Ganoderma lucidum polysaccharides to reduce liver lipid levels.

Genotyping identifies subjects with decreased MIF expression for targeted agonist therapy that prevents energy depletion during tissue ischemia.

Electrokinetically-generated oxygen-enriched fluids modulate cellular membrane potential and conductivity to treat inflammatory neurodegenerative conditions.

Antisense oligonucleotides modulate IDUA expression by binding natural antisense transcripts to restore enzyme function.

Amino acid ester prodrugs of steroidal C-17 inhibitors resolve liver toxicity and low bioavailability trade-offs in prostate cancer treatment.

Thiazole compounds induce UCP1 expression to promote white adipose tissue browning while reducing side effects associated with conventional agents.

A method disperses functionalized polysaccharides in water and heats the mixture to trigger self-assembly into nanohydrogels.

Dimethylacetamide dissolves carborane porphyrins to prevent precipitation during aqueous infusion.

Receptor activating compounds stimulate endogenous GLP-1, GIP, and PYY secretion via olfactory and free fatty acid receptor binding.